.99	1 .	. 1	1
0	6-0	1 · †	-01

7.

Utility **Patent Application** Transmittal

	A CONTRACTOR OF THE CONTRACTOR
Attorney Docket Number	IRV. DIV2
First Named Inventor	Hiserodt et al.
Title	Cancer Immunotherapy Using Autologous Tumor Cells
Express Mail Label No.	EL 923 480 208 US

nonprovisional applications	s under 37 CFR 1.53(b)
APPLICATION	ELEMENTS

MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:	Box Patent Application
ADDITEOU TO.	Washington, DC 20231

■ Pee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27.

Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

Total Specification (preferred arrangement set forth below) **Pages** - Descriptive title of the invention

a. Computer Readable Form (CRF)

- Cross Reference to Related Applications

Specification Sequence Listing on:

Statement Regarding Fed sponsored R&D

CD-Rom or CD-R (2 copies); or

CD-ROM or CD-R in duplicate, large table or Computer

- Reference to sequence listing, a table, or a computer program listing appendix

Statements verifying identity of above copies

Background of the Invention

Assignment Papers (cover sheet & documents(s))

ACCOMPANYING APPLICATION PARTS

- Brief Summary of the Invention - Brief Description of the Drawings (if filed)

> 37 CFR 3.73(b) Statement 10. (when there is an assignee)

Power of Attorney

Citations

- Detailed Description

- Claims(s)

3. 🔽

English Translation Document (if applicable) 11. Г

Copies of IDS

- Abstract of the Disclosure ١ā N) Drawing(s) (35 U.S.C. 113)

Oath or Declaration _____

8

12. Statement (IDS)/PTO-1449 3.

Preliminary Amendment

Information Disclosure

Newly executed (original or copy)

Return Receipt Postcard (MPEP 503) 14. (should be specifically itemized)

Copy from a prior application (37 CFR V 1.63(d))

Certified Copy of Priority Document(s) 15. F (if foreign priority is claimed)

DELETION OF INVENTOR(S) i. 🗀 Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR

Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). 16. F Applicant must attach form PTO/SB/35 or its equivalent

1.63(d)(2) and 1.33(b) 5. Application Data Sheet, See 37 CFR 1.76

17. \Box Other:

18. ∮∮a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Divisional Continuation

Continuation-in-part (CIP)

08/901,225 Filed July 24, 1997 of prior application No:

Prior Application Information:

in

08/901.225

Examiner

Total

Sheets

Total

G. Bansal

Group Art Unit:

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

> Fee Calculation **CLAIMS AS FILED**

For #Filed # Allowed #Extra Rate 30 **Total Claims** \$90 -20= 10 9.00 Indep. Claims 3 -3= 0

Multiple Dependent Claims (check If applicable)

BASIC FEE

\$355.00

OTHER FEE (specify purpose)

TOTAL FILING FEE \$

445.00

The Commissioner is authorized to charge any fees which may be required, or credit any overpayment to Deposit Account 50-0315. If additional fees are required, including extensions of time, please consider this a petition therefore. A duplicate copy of this sheet is enclosed

Request That Approaction Not Be Published Pursuant To 35 U.S.C. 122(2)

19. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the

subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director

of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application

being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

19. CORRESPONDENCE ADDRESS

Name (Print/Type)	Carol L.	Francis		Registration No.	36,513	
Signature	Carol	4 sauce	1		Date	teme 5,2001
Firm Name	Bozicevic, Field	R Francis LLP		Address	200 Middle	efield Road, Suite 200
City _i Menlo Park State		California		zip	94025	
Telephone	650-327-34	00	-	Fax	650-327-323	31

W. W. W.

iħ

In